Nova Patents
PL330862A1

Clinical application of proteinous kinase c in order to increase clinical effectiveness of anticarcinogenic pharmaco- and radiotherapy

Abstract

A method for treating neoplasms is disclosed, particularly using the beta -isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2''-ethoxy)-3'''(O)-4'''-(N,N-dimethylamino)-buta ne)-bis-(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.

Term

Term ended

Projected expiry passed 1 May 2017, 9.4 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

92 members in 24 offices

This recordMember, by publication datePriority claim14 more offices are in the list below

Priority claims8

Priority claims
DocumentOfficeKindDate
1665896United States of AmericaP
1665896United States of AmericaP
84173897United States of AmericaA
84173897United States of AmericaA
841738–––
60016658–––
US19960016658P–––
US19970841738–––

Members92

Family members, oldest first
DocumentOfficeKind
CA2253263A1CanadaA1
CA2253608A1CanadaA1
CA2253613A1CanadaA1
WO9740830A1World Intellectual Property Organization (WIPO)A1
WO9740831A1World Intellectual Property Organization (WIPO)A1
WO9740842A1World Intellectual Property Organization (WIPO)A1
AU2935597AAustraliaA
AU2936197AAustraliaA
AU3000297AAustraliaA
NO985065D0NorwayD0
NO985066D0NorwayD0
NO985067D0NorwayD0
NO985066LNorwayL
NO985067LNorwayL
NO985065LNorwayL
PL329851A1PolandA1
EA199800971A1Eurasian Patent Organization (EAPO)A1
EP0914135A1European Patent Office (EPO)A1
EP0915698A1European Patent Office (EPO)A1
PL330463A1PolandA1
EP0918519A1European Patent Office (EPO)A1
PL330862A1This recordPolandA1
EA199800969A1Eurasian Patent Organization (EAPO)A1
EA199800970A1Eurasian Patent Organization (EAPO)A1
CN1222850AChinaA
CZ344398A3CzechiaA3
EP0915698A4European Patent Office (EPO)A4
EP0918519A4European Patent Office (EPO)A4
BR9710704ABrazilA
BR9710705ABrazilA
BR9710706ABrazilA
IL126768D0IsraelD0
IL126836D0IsraelD0
IL126837D0IsraelD0
CN1233177AChinaA
CZ349998A3CzechiaA3
CZ350098A3CzechiaA3
HU9902315A2HungaryA2
HUP9902315A2HungaryA2
HU9902315A3HungaryA3
HUP9902315A3HungaryA3
HU9902805A2HungaryA2
HUP9902805A2HungaryA2
HK1020017A1Hong Kong, ChinaA1
AU718098B2AustraliaB2
HU9902805A3HungaryA3
HUP9902805A3HungaryA3
NZ332645ANew ZealandA
NZ332833ANew ZealandA
JP2000510828AJapanA
NZ332563ANew ZealandA
US6114320AUnited States of AmericaA
AU724923B2AustraliaB2
JP2000514402AJapanA
KR20000065171ARepublic of KoreaA
KR20000065172ARepublic of KoreaA
KR20000065223ARepublic of KoreaA
EP0914135A4European Patent Office (EPO)A4
US6232299B1United States of AmericaB1
US2001001791A1United States of AmericaA1
AU736333B2AustraliaB2
EA001752B1Eurasian Patent Organization (EAPO)B1
EA001779B1Eurasian Patent Organization (EAPO)B1
US6284751B1United States of AmericaB1
US6288053B1United States of AmericaB1
HU0100285A2HungaryA2
HUP0100285A2HungaryA2
JP2002504086AJapanA
NZ504136ANew ZealandA
US6486179B2United States of AmericaB2
KR100364487B1Republic of KoreaB1
UA54427C2UkraineC2
HU0100285A3HungaryA3
HUP0100285A3HungaryA3
IL126836AIsraelA
EP0918519B1European Patent Office (EPO)B1
AT270548TAustriaT
ATE270548T1AustriaT1
CN1158073CChinaC
DE69729798D1GermanyD1
PT918519EPortugalE
DK0918519T3DenmarkT3
SI0918519T1SloveniaT1
ES2224249T3SpainT3
PL189020B1PolandB1
DE69729798T2GermanyT2
CZ296711B6CzechiaB6
NO322209B1NorwayB1
NZ538109ANew ZealandA
CA2253613CCanadaC
JP4122060B2JapanB2
HU226378B1HungaryB1